References
- Aalen, O. O. (1978). Nonparametric inference for a family of counting processes. Annals of Statistics 6:701–726.
- Cox, D. R. (1972). Regression models and life tables (with discussion). Journal of Royal Statistical Society B 34:187–220.
- Fleming, T. R., Harrington, D. P. (1991). Counting Processes and Survival Analysis.New York: Wiley.
- Freidlin, B., McShane, L. M., Korn, E. L. (2010). Randomized clinical trials with biomarkers: Design issues. The Journal of the National Cancer Institute 102:152–160
- Freidlin, B., McShane, L. M., Polley, M. Y. C., Korn, E. L. (2012). Randomized phase II trial designs with biomarkers. Journal of Clinical Oncology 30:3304–3309.
- Jung, S. H. (2013). Randomized Phase II Cancer Clinical Trials. New York, NY: Chapman & Hall/CRC.
- Jung, S. H., Chow, S. C. (2012). On sample size calculation for comparing survival curves under general hypotheses testing. Journal of Biopharmaceutical Statistics 22:485–495.
- Jung, S. H., Kang, S. J., McCall, L., Blumenstein, B. (2005). Sample size computation for noninferiority log-rank test. Journal of Biopharmaceutical Statistics 15:957–967.
- Maitournam, A., Simon, R. (2005). On the efficiency of targeted clinical trials. Statistics in Medicine 24(3):329–339.
- Mandrekar, S. J., Sargent, D. J. (2009). Clinical trial designs for predictive biomarker validation: Theoretical considerations and practical challenges. Journal of Clinical Oncology 27(24):4027–4034.
- Nelson, W. (1969). Hazard plotting for incomplete failure data. Journal of Quality Technology 1:27–52.
- Ozasa, H., Oguri, T., Uemura, T., Miyazaki, M., Maeno, K., Sato, S., Ueda, R. (2010). Significance of thymidylate synthase for resistance to pemetrexed in lung cancer. Cancer Science 101:161–166.
- Peto, R., Peto, J. (1972). Asymptotically efficient rank invariant test procedures (with discussion). Journal of the Royal Statistical Society, Series A 135:185–206.
- Simon, R., Maitournam, A. (2004). Evaluating the efficiency of targeted designs for randomized clinical trials. Clinical Cancer Research 15;10(20):6759–6763.
- Sun, J. M., Ahn, J. S., Jung, S. H., Sun, J., Ha, S. Y., Han, J., Park, K., Ahn, M. J. (2015). Pemetrexed plus cisplatin versus gemcitabine plus cisplatin according to thymidylate synthase expression in nonsquamous nonsmall-cell lung cancer: A biomarker-stratified randomized phase II trial. Journal of Clinical Oncology 33:2450–2456.
- Sun, J. M., Han, J., Ahn, J. S., Park, K., Ahn, M. J. (2011). Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. Journal of Thoracic Oncology 6:1392–1399.
- Yateman, N. A., Skene, A. M. (1992). Sample size for proportional hazards survivalstudies with arbitrary patient entry and loss to follow-up distributions. Statistics in Medicine 11:1103–1113.